YOCHAI BIRNBAUM, MD
Osteopathic Medicine at Dryden Rd, Houston, TX
License number
Texas M1517
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
1709 Dryden Rd, Houston, TX 77030
Phone
(713) 798-2735
(713) 798-0270 (Fax)
(713) 798-0270 (Fax)
Professional information
Yochai Birnbaum, Houston TX
Specialties:
Cardiologist
Address:
6620 Main St, Houston, TX 77030
1709 Dryden Rd, Houston, TX 77030
1709 Dryden Rd, Houston, TX 77030
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Cardiovascular Disease (Internal Medicine)
Methods Of Increasing Camp Levels And Uses Thereof
US Patent:
2011009, Apr 21, 2011
Filed:
Oct 19, 2009
Appl. No.:
12/589153
Inventors:
Yochai Birnbaum - Houston TX, US
International Classification:
A61K 31/675, A61K 31/4985, A61K 31/40, A61K 31/403, A61K 31/4439, A61K 31/47, A61K 31/4402, A61K 31/4166, A61K 31/435, A61K 31/404, A61K 31/366, A61P 9/10
US Classification:
514 81, 514249, 514423, 514412, 514342, 514312, 514334, 514392, 514277, 514419, 514460
Abstract:
The present invention shows that cilostazol, a phosphodiesterase 3 inhibitor has additional beneficial effects to atorvastatin on myocardial remodeling by inducing and preserving eNOS phosphorylation. The present invention demonstrates a cardioprotective effect of Cilostazol indicating the therapeutic potency of this drug. In addition, the present invention demonstrates that the additional effect of Cilostazol and atorvastatin therapy against ischemia injury is due to the augmentation of phosphatodylicositol 3-kinase/AKT (PI3-/AKT), PKA and p-eNOS signaling.
Methods Of Treating Vascular Disease And Injury
US Patent:
2010029, Nov 18, 2010
Filed:
May 17, 2010
Appl. No.:
12/800520
Inventors:
Yochai Birnbaum - Houston TX, US
Yumei Ye - League City TX, US
Yumei Ye - League City TX, US
International Classification:
A61K 31/4439, A61K 31/7088, A61P 9/10
US Classification:
514342, 514 44 A
Abstract:
The present invention provides a method of treating a vascular disease or injury in an individual in need of such treatment, comprising the step of administering a compound or composition that down-regulates or decreases the activity of microRNA-29 in the individual. Also provided is a method of down-regulating or decreasing the activity of microRNA-29 in an individual in need of such treatment, comprising the step of administering a PPAR-γ agonist compound or PPAR-γ agonist containing composition that down-regulates or decreases the activity of microRNA-29 in the individual. Further provided is a method of treating a vascular disease or injury in an individual in need of such treatment, comprising the step of administering a microRNA-29 antagonist that down-regulates or decreases the activity of microRNA-29 in said individual.
Ultrasonic Bath To Increase Tissue Perfusion
US Patent:
2010006, Mar 11, 2010
Filed:
Dec 19, 2007
Appl. No.:
12/520041
Inventors:
Robert J. Siegel - Beverly Hills CA, US
Yochai Birnbaum - Houston TX, US
Huai Luo - Los Angeles CA, US
Yochai Birnbaum - Houston TX, US
Huai Luo - Los Angeles CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM - Austin TX
BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM - Austin TX
International Classification:
A61N 7/00
US Classification:
601 2
Abstract:
The present invention describes a method of using an ultrasonic bath to enhance tissue perfusion, enhance the development of collateral blood vessels and/or enhance collateral circulation in an extremity in need thereof. Also described is an ultrasonic bath adapted to hold media and to permit the immersion of an extremity and comprising one or more ultrasonic transducers to generate and transmit ultrasonic energy to the extremity or the inventive method
Phosphorylation Of 5-Lipoxygenase At Ser523 And Uses Thereof
US Patent:
2009004, Feb 12, 2009
Filed:
Dec 6, 2007
Appl. No.:
11/999534
Inventors:
Yochai Birnbaum - Houston TX, US
International Classification:
A61K 31/555, A61K 31/495, C12Q 1/26, A61P 9/00, A61K 31/425, C12Q 1/48
US Classification:
514184, 514249, 435 25, 435 15, 514369
Abstract:
The present invention provides novel mechanisms that regulate the production of anti-inflammatory and pro-inflammatory mediators generated by 5-lipoxygenase. In this regard, the present invention establishes that phosphorylation of 5-Lipoxygenase by protein kinase A, has a crucial role in determining the end products of 5-Lipoxygenase. With translocation to the nucleus, potent proinflammatory leukotrienes are produced, whereas following phosphorylation by protein kinase A, anti-inflammatory mediators are produced. The present invention also discloses compounds that regulate these pro- and anti-inflammatory mediators.
Uses Of Selective Cyclooxygenase-1 Inhibitors
US Patent:
2008005, Feb 28, 2008
Filed:
Jul 18, 2007
Appl. No.:
11/879634
Inventors:
Yochai Birnbaum - Houston TX, US
International Classification:
A61K 31/497, A61K 31/05, A61K 31/35, A61K 31/506, A61P 9/00, A61K 31/40, A61K 31/415
US Classification:
514254020, 514275000, 514342000, 514406000, 514419000, 514460000, 514733000
Abstract:
The present invention discloses effect of non-selective COX1 inhibitor such as aspirin, statins, thiazolidinediones or combinations thereof on COX2. Also disclosed herein is a method to avoid the adverse effects that the non-selective COX1 inhibitor may have when administered with statins and/or thiazolidinediones.
Methods And Compositions For Treatment Of Reperfusion Injury And Other Cardiac Conditions
US Patent:
2011013, Jun 2, 2011
Filed:
Apr 30, 2008
Appl. No.:
12/598131
Inventors:
Yochai Birnbaum - Houston TX, US
Barry F. Uretsky - Fort Smith AR, US
Barry F. Uretsky - Fort Smith AR, US
Assignee:
The Board of Regents of the University of Texas Sy - Austin TX
International Classification:
A61K 38/17, A61K 38/08, A61P 9/10, A61P 9/00
US Classification:
514 164, 514 213
Abstract:
The present invention discloses methods to prevent and treat cardiovascular disorders, hi certain aspects the methods are drawn to releasing endogenous calcitonin-gene related peptide from intrinsic cardiac adrenergic cells within the heart. In further aspects, a combination of a βadrenergic receptor agonist β-AR agonist) and a vasodilator can be used in treating reperfusion injury.